指南与共识乳腺癌

中国晚期乳腺癌规范诊疗指南(2020版)

[Guidelines for clinical diagnosis and treatment of advanced breast cancer in China (2020 Edition)].
指南 / 共识 · Zhonghua Zhong Liu Za Zhi · 2020-01-01

中国乳腺癌诊疗专家组基于国内外研究进展和真实世界数据,在2018版基础上更新制定了《中国晚期乳腺癌规范诊疗指南(2020版)》。该指南针对不可手术的局部晚期和复发或转移性乳腺癌的诊断、治疗及预后给出推荐,旨在为临床医师提供参考。

要点

  • 2015年中国女性新发乳腺癌约30.4万例,死亡约7万余例。
  • 约3%~10%的新发患者确诊时即有远处转移,早期患者中约30%可发展为晚期。
  • 晚期乳腺癌5年生存率仅20%,中位总生存时间2~3年。

核心结论

  • 晚期乳腺癌虽难以治愈,但可通过新型治疗药物和优化治疗模式缓解症状、改善生活质量并延长生存。
  • 一、二线解救治疗后缺乏标准方案,本指南为不可手术局部晚期和复发或转移性乳腺癌提供诊疗参考。

研究设计与样本

  • 中国乳腺癌诊疗专家组制定,基于2018版指南及国内外研究进展和真实世界临床数据更新。

主要发现

  • 2015年中国女性乳腺癌新发约30.4万例,死亡约7万余例。
  • 新发乳腺癌中约3%~10%确诊时即有远处转移,早期患者中约30%可发展为晚期。
  • 晚期乳腺癌5年生存率仅20%,中位总生存时间2~3年。

关键数值与推荐

  • 指南对不可手术的局部晚期和复发或转移性乳腺癌的诊断、治疗及预后给出推荐。

临床怎么用

  • 临床医师可参照本指南为晚期乳腺癌患者选择合理治疗方案。

局限性

  • 一、二线解救治疗后缺乏标准治疗方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Breast cancer is the most common malignant tumor among women all over the world. In 2015, there were about 304, 000 new cases of breast cancer in Chinese female, with more than 70, 000 deaths. Of the new cases of breast cancer each year, about 3% to 10% of patients have distant metastasis at the time of diagnosis. Of the early-stage patients, about 30% developed into advanced breast cancer. The 5-years survival rate of advanced breast cancer was only 20%, and the median overall survival time was 2-3 years. Although advanced breast cancer is difficult to cure at present, we can alleviate the clinical symptoms of patients, improve their quality of life and further prolong their survival time by developing new therapeutic drugs and optimizing treatment models, to achieve the purpose of long-term survival with tumor. It is very important for patients with advanced breast cancer to choose the reasonable treatment plan. Since there is lack of standard recommendation for the treatment of advanced breast cancer after the first and second line chemotherapy, according to the research progress of breast cancer at home and abroad and the update of real-world clinical research data, the Chinese expert group analyzed, summarized and discussed the relevant research data, updated the diagnosis, treatment and prognosis of inoperable locally advanced and recurrent or metastatic breast cancer on the basis of version 2018, and formulated the "Guidelines for clinical diagnosis and treatment of advanced breast cancer in China (2020 Edition)" (ABCC 2020) for clinicians' reference. 乳腺癌是全球女性最常见的恶性肿瘤,2015年中国女性新发乳腺癌病例约30.4万例,死亡约7万余例。在每年新发乳腺癌病例中,约3%~10%的患者在确诊时即有远处转移。早期患者中约有30%可发展为晚期乳腺癌。乳腺癌患者的晚期5年生存率仅为20%,总体中位生存时间为2~3年。晚期乳腺癌虽难以治愈,但可通过研发新型治疗药物、优化治疗模式等方法来缓解患者的临床症状,改善患者的生活质量,进一步延长患者的生存时间,以期达到长期带瘤生存的目的。晚期乳腺癌患者治疗方案的选择非常重要,且因为一、二线解救治疗后缺乏标准治疗方案,中国乳腺癌诊疗专家组根据国内外乳腺癌研究进展、真实世界临床数据更新,进行认真分析、讨论和总结,对不可手术的局部晚期和复发或转移性乳腺癌诊断、治疗及预后等方面在2018版基础上进行更新,制定《中国晚期乳腺癌规范诊疗指南(2020版)》(ABCC 2020),以供临床医师参考。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. [Guidelines for clinical diagnosis and treatment of advanced breast cancer in China (2020 Edition)]. Zhonghua Zhong Liu Za Zhi. 2020. PMID: 33113619. doi:10.3760/cma.j.cn112152-20200817-00747

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。